Comparative Pharmacology
Head-to-head clinical analysis: SEYSARA versus TETRACHEL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SEYSARA versus TETRACHEL.
SEYSARA vs TETRACHEL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sarecycline is a tetracycline-class antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the addition of amino acids to the growing peptide chain. It also has anti-inflammatory properties through inhibition of neutrophil chemotaxis and reduction of pro-inflammatory cytokines.
Tetracycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the attachment of aminoacyl-tRNA to the mRNA-ribosome complex.
100 mg orally once daily with food.
500 mg orally once daily for 28 days; for severe infections, 500 mg twice daily for 14 days.
None Documented
None Documented
The terminal elimination half-life after oral administration is approximately 12 hours (range 10-14 hours), supporting once-daily dosing.
6-11 hours (prolonged in renal impairment; up to 57 hours in anuria).
Renal excretion of unchanged drug accounts for approximately 66% of the administered dose; fecal elimination is about 33%.
Renal 60% (glomerular filtration), fecal 40% (biliary excretion of active drug and metabolites).
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic